← Human Trials & Peer-Reviewed Studies
Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker
Plain-language guide to PMID 18390891 (2008): double-blind randomized controlled trial study of Angiotensin II.
Key Facts
- PMID
- 18390891
- Journal
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Zhu S et al. (4 authors)
- DOI
- 10.1093/ndt/gfn159
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II in this randomized controlled trial publication.
This study aimed to investigate the relationship between TGF-beta(1) levels and kidney damage and renoprotective effects of angiotensin-converting enzyme inhibitor and/or angiotensin II type 1 receptor blocker in patients with essential hypertension (EH).
Who Took Part
PubMed indexes the participants as middle-aged adults, both men and women.
A total of 156 patients with EH were enrolled and grouped according to albumin-to-creatinine ratio (ACR).
Of these, 90 patients with EH underwent a 12-week antihypertensive trial with administration of benazepril, valsartan or both.
How the Study Was Run
The researchers set it up as a randomized and double-blind study.
Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.
Serum TGF-beta(1), plasma angiotensin (Ang) II and urinary albumin were quantified by immunoassays.
What Was Measured
The subject headings attached to it are Administration, Inhalation, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Benzazepines, Hypertension and Kidney.
What This Means in Plain Language
The paper is a randomized and double-blind study of Angiotensin II.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2008 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.